"uuid:ID","name","id","rationale","instanceType","description","label"
"c5663dcc-22f2-4575-95e6-dd89105c7aae","Study Design 1","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","The main design for the study",""
